|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RGS19 |
Gene summary for RGS19 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RGS19 | Gene ID | 10287 |
| Gene name | regulator of G protein signaling 19 | |
| Gene Alias | GAIP | |
| Cytomap | 20q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0006914 | UniProtAcc | P49795 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10287 | RGS19 | LZE4T | Human | Esophagus | ESCC | 8.54e-08 | 1.77e-01 | 0.0811 |
| 10287 | RGS19 | LZE7T | Human | Esophagus | ESCC | 1.48e-02 | 2.06e-01 | 0.0667 |
| 10287 | RGS19 | LZE22T | Human | Esophagus | ESCC | 1.61e-04 | 3.37e-01 | 0.068 |
| 10287 | RGS19 | LZE24T | Human | Esophagus | ESCC | 2.96e-10 | 2.98e-01 | 0.0596 |
| 10287 | RGS19 | LZE6T | Human | Esophagus | ESCC | 9.33e-05 | 3.57e-01 | 0.0845 |
| 10287 | RGS19 | P1T-E | Human | Esophagus | ESCC | 7.09e-06 | 3.05e-01 | 0.0875 |
| 10287 | RGS19 | P2T-E | Human | Esophagus | ESCC | 3.09e-05 | 1.13e-01 | 0.1177 |
| 10287 | RGS19 | P4T-E | Human | Esophagus | ESCC | 9.52e-14 | 3.44e-01 | 0.1323 |
| 10287 | RGS19 | P5T-E | Human | Esophagus | ESCC | 1.65e-16 | 3.45e-01 | 0.1327 |
| 10287 | RGS19 | P8T-E | Human | Esophagus | ESCC | 4.17e-04 | 1.36e-01 | 0.0889 |
| 10287 | RGS19 | P9T-E | Human | Esophagus | ESCC | 8.54e-08 | 2.15e-01 | 0.1131 |
| 10287 | RGS19 | P10T-E | Human | Esophagus | ESCC | 3.76e-20 | 3.90e-01 | 0.116 |
| 10287 | RGS19 | P11T-E | Human | Esophagus | ESCC | 3.02e-12 | 5.48e-01 | 0.1426 |
| 10287 | RGS19 | P12T-E | Human | Esophagus | ESCC | 3.62e-14 | 2.64e-01 | 0.1122 |
| 10287 | RGS19 | P15T-E | Human | Esophagus | ESCC | 2.61e-12 | 2.21e-01 | 0.1149 |
| 10287 | RGS19 | P16T-E | Human | Esophagus | ESCC | 5.75e-12 | 3.29e-01 | 0.1153 |
| 10287 | RGS19 | P17T-E | Human | Esophagus | ESCC | 3.33e-04 | 2.44e-01 | 0.1278 |
| 10287 | RGS19 | P19T-E | Human | Esophagus | ESCC | 1.51e-03 | 4.09e-01 | 0.1662 |
| 10287 | RGS19 | P20T-E | Human | Esophagus | ESCC | 1.89e-16 | 3.70e-01 | 0.1124 |
| 10287 | RGS19 | P21T-E | Human | Esophagus | ESCC | 1.77e-32 | 7.93e-01 | 0.1617 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0097305111 | Esophagus | ESCC | response to alcohol | 138/8552 | 253/18723 | 2.70e-03 | 1.14e-02 | 138 |
| GO:009730519 | Oral cavity | OSCC | response to alcohol | 127/7305 | 253/18723 | 1.81e-04 | 1.24e-03 | 127 |
| GO:0097305110 | Oral cavity | LP | response to alcohol | 80/4623 | 253/18723 | 7.24e-03 | 4.05e-02 | 80 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RGS19 | SNV | Missense_Mutation | c.299N>A | p.Gly100Glu | p.G100E | P49795 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| RGS19 | SNV | Missense_Mutation | rs577731145 | c.163N>T | p.Arg55Trp | p.R55W | P49795 | protein_coding | deleterious(0) | probably_damaging(0.918) | TCGA-AA-3534-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RGS19 | SNV | Missense_Mutation | rs762327545 | c.569G>A | p.Arg190Gln | p.R190Q | P49795 | protein_coding | tolerated(0.05) | possibly_damaging(0.907) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RGS19 | SNV | Missense_Mutation | c.325N>T | p.Arg109Trp | p.R109W | P49795 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RGS19 | SNV | Missense_Mutation | novel | c.94N>A | p.Ala32Thr | p.A32T | P49795 | protein_coding | tolerated_low_confidence(0.5) | benign(0.003) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RGS19 | SNV | Missense_Mutation | novel | c.365C>T | p.Ala122Val | p.A122V | P49795 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AX-A1C4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RGS19 | SNV | Missense_Mutation | c.296N>T | p.Ala99Val | p.A99V | P49795 | protein_coding | tolerated(0.06) | benign(0.015) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RGS19 | SNV | Missense_Mutation | rs772494306 | c.314N>A | p.Arg105Gln | p.R105Q | P49795 | protein_coding | deleterious(0.04) | possibly_damaging(0.466) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| RGS19 | SNV | Missense_Mutation | novel | c.347A>G | p.Asn116Ser | p.N116S | P49795 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RGS19 | SNV | Missense_Mutation | rs749194018 | c.479G>A | p.Arg160His | p.R160H | P49795 | protein_coding | tolerated(0.06) | possibly_damaging(0.693) | TCGA-86-8279-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | etoposide | CR |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 10287 | RGS19 | NA | opioids |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |